Gubra shares rise as Boehringer starts Phase 2 trial of obesity drug BI 3034701, triggers EUR 10 million milestone

• Gubra partner Boehringer Ingelheim started a Phase 2 trial of BI 3034701 for overweight and obesity.
• Program targets GLP-1, GIP, NPY2 receptors; positioned as a potential first-in-class triple agonist.
• Phase 2 start triggers a EUR 10 million milestone payment to Gubra.
• Boehringer Ingelheim retains responsibility for further development and global commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.